Razaxaban hydrochloride is primarily investigated for its anticoagulant properties, making it a potential candidate for preventing and treating thromboembolic disorders. It works by inhibiting Factor Xa, a key enzyme in the blood coagulation cascade, thereby reducing the risk of blood clot formation. This mechanism is particularly useful in conditions such as deep vein thrombosis, pulmonary embolism, and stroke prevention in patients with atrial fibrillation. Its application is also being explored in post-surgical settings to minimize the risk of clot-related complications. Additionally, it may offer advantages in patients requiring long-term anticoagulation therapy due to its targeted action and potential for reduced bleeding risks compared to traditional anticoagulants. Research continues to evaluate its efficacy, safety, and potential use in various cardiovascular and thrombotic conditions.